GSK is in 1st place for the fourth time, performing strongly across the board and with several innovative practices. It has a large relevant portfolio and leads in R&D, dedicating a large pipeline share to diseases in scope. It is developing many products in partnerships based on access provisions. It also participates in numerous IP-sharing partnerships and leads in access-to-medicine management. GSK no longer leads in Capability Advancement or Pricing, Manufacturing & Distribution. While it has equitable pricing for many relevant products, it does not always provide detailed evidence of how it targets its strategies toward affordability for the lowest tier. GSK also falls in Public Policy & Market Influence, with evidence of multiple breaches.